Here are three things to know:
1. SpinalCyte is a tissue engineering technology company focused on developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts.
2. Howard An, MD, director, division of spine surgery and spine fellowship program at Rush University Medical Center in Chicago is the principal investigator of the studies, which began in 2014.
3. Dr. An’s team is reporting a significant increase in disc height indexes in the discs treated with human dermal fibroblasts.
More articles on devices:
InVivo continues to see success with INSPIRE study—5 observations
Stryker gears up its challenge at first stop on PGA Tour: 3 notes
Amedica, Stryker, SI-BONE & & more: 12 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
